Managing bipolar depression was always risky with antidepressants. Spravato addressed the low without triggering anything else. Dr. Rueda coordinated with my psychiatrist the whole way through.
S.M.
White Plains, NY
Real results from real patients.
PMC Psychedelic has completed over 5,000 treatments. Our outcomes speak for themselves.
The numbers behind the treatment.
These outcomes are drawn from published clinical research on Spravato and Ketamine IV therapy, as well as PMC Psychedelic's own patient history. We don't promise results, but we do share the evidence.
75–83%
Efficacy rate for treatment-resistant depression across ketamine modalities
5,000+
Treatments completed at PMC Psychedelic since opening
Near-Perfect
Patient satisfaction based on verified Google Reviews
What the clinical evidence shows.
Spravato and Ketamine IV are not experimental. They are FDA-approved or well-supported treatments with substantial peer-reviewed research behind them. The following findings reflect the clinical literature, not promises from PMC.
Spravato — FDA Approval
Breakthrough Therapy
The FDA granted Breakthrough Therapy designation for esketamine in 2016. Spravato received full FDA approval in 2019 for treatment-resistant depression and in 2020 for MDD with acute suicidal ideation.
Source: FDA.gov
Rapid Onset
Hours, Not Weeks
Unlike standard antidepressants that may take 4 to 6 weeks to produce measurable effects, ketamine-based treatments typically produce meaningful improvement within 24 to 48 hours of an early session.
Source: Published clinical literature
Treatment-Resistant Cases
70–83% Response
Multiple clinical trials show 70 to 83% of patients with treatment-resistant depression experience meaningful improvement with ketamine-based therapy — patients who had already failed multiple other treatments.
Source: NEJM, JAMA Psychiatry, multiple peer-reviewed trials
Glutamate Mechanism
A Different Pathway
Multiple clinical trials show 70 to 83% of patients with treatment-resistant depression experience meaningful improvement with ketamine-based therapy — patients who had already failed multiple other treatments.
Source: Neuroscience literature
Outcomes across the conditions we treat.
PMC Psychedelic treats a range of mental health conditions. Response rates and clinical evidence vary by condition — here is an honest summary of what the research shows.
| Condition | Response Rate | Clinical Notes |
|---|---|---|
| Treatment-Resistant Depression | 75–83% | Across Spravato and Ketamine IV modalities at PMC Psychedelic |
| Major Depressive Disorder | 70%+ | With acute suicidal ideation — FDA-approved Spravato indication |
| PTSD | 50% or more reduction in symptoms | Rapid reduction in hyperarousal and intrusive symptoms |
| Anxiety Disorders | 50% or more reduction in symptoms | Particularly for generalized anxiety and panic disorders |
| OCD | Emerging evidence | Ketamine IV shows promise for treatment-resistant OCD |
| Bipolar Depression | Active use | Depressive phase — treated carefully alongside mood stabilizers |
Response rates reflect outcomes in published clinical research and PMC Psychedelic patient experience — they are not guaranteed for every individual. Dr. Rueda will give you an honest assessment of what is realistic for your specific situation during your consultation.
What our patients say.
PMC Psychedelic has received near-perfect ratings across Google Reviews. These are real patients writing about their real experiences — unsolicited and unedited.
I had been struggling with depression and thoughts of suicide for over a year. After Spravato sessions at PMC, I noticed a shift that I hadn't felt in a long time. Dr. Rueda's team was caring and thorough.
A.M.
Westchester County, NY
How we measure whether treatment is working.
Dr. Rueda does not consider a course of treatment successful just because a patient completes the sessions. We track outcomes using standardized clinical assessment tools and have honest conversations with patients about whether treatment is producing the results they need.
If a patient is not responding after an adequate trial, we say so. We do not continue treatment that is not working. We do not have a financial interest in prolonging treatment that isn't helping.
“The goal is improvement that the patient can feel. If we're not seeing that, we have a different conversation.”
— Dr. Carlos Rueda, MD, MBA Medical Director, PMC Psychedelic
Get Started
Ready to see what's possible?
The best way to understand whether ketamine-based therapy might work for you is to talk to Dr. Rueda directly. Book a consultation and our team will verify your insurance, answer your questions, and give you an honest assessment — before anything is scheduled.
PMC Psychedelic · Port Chester, NY · 914-928-2913
